Travere Therapeutics TVTX announced that the FDA ... approval to its oral non-immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...

Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD ... which claimed the first FDA approval for a drug treatment for HFpEF in February.

Novartis NVS announced that the FDA has approved breast ... with node-negative (N0) disease. Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the ...

1 Ribociclib is manufactured by Novartis for ... 3 “The FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, is a pivotal moment in improving our ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

The U.S. Food and Drug Administration has approved a new drug for ... causes of disability worldwide, the FDA reports. Individuals with this disease have a greater risk of dying young, and nearly ...